Mativ Holdings, Inc.

DB:MH2 Stock Report

Market Cap: €645.0m

Mativ Holdings Valuation

Is MH2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MH2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MH2 (€12) is trading below our estimate of fair value (€38.25)

Significantly Below Fair Value: MH2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MH2?

Key metric: As MH2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MH2. This is calculated by dividing MH2's market cap by their current revenue.
What is MH2's PS Ratio?
PS Ratio0.3x
SalesUS$1.97b
Market CapUS$680.28m

Price to Sales Ratio vs Peers

How does MH2's PS Ratio compare to its peers?

The above table shows the PS ratio for MH2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
SIM0 SIMONA
0.6xn/a€354.0m
FPE3 Fuchs
1.6x3.6%€5.1b
IBU IBU-tec advanced materials
0.7x19.2%€33.0m
ACT AlzChem Group
1.1x7.5%€608.5m
MH2 Mativ Holdings
0.3x1.7%€680.3m

Price-To-Sales vs Peers: MH2 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does MH2's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x2.7%US$128.40m
NSAK OTI Greentech
0.03xn/aUS$602.27k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
MH2 0.3xIndustry Avg. 1.0xNo. of Companies5PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MH2 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is MH2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MH2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: MH2 is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MH2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€12.00
€16.38
+36.5%
11.7%€19.08€14.79n/a3
Nov ’25€13.90
€22.32
+60.6%
22.4%€27.34€17.31n/a2
Oct ’25€14.90
€22.32
+49.8%
22.4%€27.34€17.31n/a2
Sep ’25€17.00
€22.32
+31.3%
22.4%€27.34€17.31n/a2
Aug ’25€17.00
€22.71
+33.6%
22.4%€27.81€17.61n/a2
Jul ’25€14.70
€22.71
+54.5%
22.4%€27.81€17.61n/a2
Jun ’25€16.40
€22.71
+38.5%
22.4%€27.81€17.61n/a2
May ’25€16.90
€22.58
+33.6%
22.4%€27.65€17.51n/a2
Apr ’25€17.10
€22.58
+32.0%
22.4%€27.65€17.51n/a2
Mar ’25€16.20
€22.58
+39.4%
22.4%€27.65€17.51n/a2
Feb ’25€10.70
€19.37
+81.1%
19.0%€23.07€15.68n/a2
Jan ’25€13.90
€19.38
+39.4%
19.0%€23.08€15.69n/a2
Dec ’24€10.60
€19.62
+85.1%
19.0%€23.36€15.88n/a2
Nov ’24€11.90
€26.03
+118.8%
5.3%€27.41€24.66€13.902
Oct ’24€13.40
€26.03
+94.3%
5.3%€27.41€24.66€14.902
Sep ’24€15.30
€26.03
+70.2%
5.3%€27.41€24.66€17.002
Aug ’24€16.20
€25.94
+60.1%
7.1%€27.79€24.08€17.002
Jul ’24€13.80
€25.94
+87.9%
7.1%€27.79€24.08€14.702
Jun ’24€13.70
€25.74
+87.9%
7.1%€27.58€23.90€16.402
May ’24€17.30
€31.72
+83.4%
2.9%€32.63€30.81€16.902
Apr ’24€19.50
€32.28
+65.6%
2.9%€33.21€31.36€17.102
Mar ’24€24.20
€33.08
+36.7%
2.9%€34.03€32.14€16.202
Feb ’24€24.60
€32.89
+33.7%
9.9%€36.14€29.65€10.702
Jan ’24€19.30
€34.65
+79.5%
12.3%€38.92€30.38€13.902

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Ecora Resources

UK£159.8m

Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.

HGR

UK£0.77

7D

8.9%

1Y

-29.0%

Central Asia Metals

UK£277.0m

Operates as a base metals producer.

9C3

UK£1.87

7D

0.5%

1Y

-4.1%

Arkema

€5.7b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€75.20

7D

-2.0%

1Y

-17.2%